stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Return on invested capital
10x Genomics's return on invested capital over the twelve months to 30 September 2026 was −17.2%, down 3.2 percentage points from fiscal 2025 (−14.0%). Over the past ten years it has ranged from −566.8% (fiscal 2020) to 0.00% (fiscal 2018); the current reading is higher than 78% of that period. That is below the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −14.0% | 24.42 |
| FY2024 | −38.4% | 8.67 |
| FY2023 | −47.1% | (18.93) |
| FY2022 | −28.1% | (13.87) |
| FY2021 | −14.3% | 552.51 |
| FY2020 | −566.8% | (492.23) |
| FY2019 | −74.5% | (74.54) |
| FY2018 | 0.00% | 9.49 |
| FY2017 | −9.49% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PODD Insulet Corporation compare | 18.8% |
| PEN Penumbra, Inc. compare | 12.7% |
| GMED Globus Medical, Inc. compare | 8.86% |
| HAE Haemonetics Corporation compare | 6.31% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BIO.B Bio-Rad Laboratories, Inc. compare | −0.44% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| TXG 10x Genomics | −20.2% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement